STERIS plc $STE Shares Bought by GDS Wealth Management

GDS Wealth Management grew its position in STERIS plc (NYSE:STE) by 4.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,697 shares of the medical equipment provider’s stock after acquiring an additional 2,855 shares during the quarter. GDS Wealth Management owned about 0.07% of STERIS worth $15,782,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Wealthspire Advisors LLC boosted its stake in STERIS by 31.1% during the 2nd quarter. Wealthspire Advisors LLC now owns 1,571 shares of the medical equipment provider’s stock worth $377,000 after purchasing an additional 373 shares during the period. Vanguard Group Inc. raised its holdings in shares of STERIS by 1.7% in the second quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after buying an additional 205,276 shares during the last quarter. Nomura Asset Management Co. Ltd. boosted its stake in shares of STERIS by 1.1% during the second quarter. Nomura Asset Management Co. Ltd. now owns 31,477 shares of the medical equipment provider’s stock worth $7,561,000 after buying an additional 336 shares during the period. Generali Investments Management Co LLC purchased a new position in shares of STERIS during the second quarter worth about $56,000. Finally, Cetera Investment Advisers increased its position in STERIS by 2.8% in the 2nd quarter. Cetera Investment Advisers now owns 7,195 shares of the medical equipment provider’s stock valued at $1,728,000 after acquiring an additional 196 shares during the period. 94.69% of the stock is owned by institutional investors and hedge funds.

STERIS Trading Down 0.8%

NYSE:STE opened at $254.94 on Thursday. STERIS plc has a 1 year low of $200.98 and a 1 year high of $268.30. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.53 and a current ratio of 2.22. The stock has a fifty day moving average price of $246.54 and a two-hundred day moving average price of $241.03. The stock has a market capitalization of $25.02 billion, a price-to-earnings ratio of 39.04 and a beta of 1.02.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping the consensus estimate of $2.38 by $0.09. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. During the same period in the previous year, the firm earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, sell-side analysts anticipate that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, November 18th. STERIS’s dividend payout ratio (DPR) is presently 36.21%.

Insider Activity at STERIS

In related news, CEO Daniel A. Carestio sold 159 shares of the company’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the sale, the chief executive officer owned 51,096 shares in the company, valued at $12,356,034.72. This represents a 0.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP John Adam Zangerle sold 15,000 shares of STERIS stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the transaction, the vice president directly owned 33,669 shares of the company’s stock, valued at approximately $8,926,998.66. This represents a 30.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.07% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have commented on STE shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Finally, Morgan Stanley upped their price objective on shares of STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $273.50.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.